🇺🇸 FDA
Patent

US 12281060

Remodilins for airway remodeling and organ fibrosis

granted A61KA61K31/18A61K31/63

Quick answer

US patent 12281060 (Remodilins for airway remodeling and organ fibrosis) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/18, A61K31/63, A61K31/635, A61K45/06